Healthcare resource utilization, adherence and persistence with antipsychotic therapy among schizophrenia patients with vs. without pre-existing metabolic syndrome

References

• Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 2006;3:A42
   PubMedGoogle Scholar
• Fenton WS, Chavez MR. Medication-induced weight gain and dyslipidemia in patients with schizophrenia. Am J Psychiatry 2006;163:1697-704
   PubMed Web of Science ®Google Scholar
• Bobes J, Arango C, Aranda P, et al. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr Res 2007;90:162-73
   PubMed Web of Science ®Google Scholar
• Daumit GL, Goff DC, Meyer JM, et al. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res 2008;105:175-87
   PubMed Web of Science ®Google Scholar
• Heart Disease and Stroke Statistics: 2009 Update-At-A-Glance. Available at: http://www.americanheart.org/downloadable/heart/1240250946756LS-1982%20Heart%20and%20Stroke%20Update.042009.pdf [Last accessed 10 May 2010]
   Google Scholar
• Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161:1334-49
   PubMed Web of Science ®Google Scholar
• American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004;65:267-72
   Google Scholar
• Jennex A, Gardner DM. Monitoring and management of metabolic risk factors in outpatients taking antipsychotic drugs: a controlled study. Can J Psychiatry 2008;53:34-42
   PubMed Web of Science ®Google Scholar
• Morrato EH, Newcomer JW, Allen RR, et al. Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data. J Clin Psychiatry 2008;69:316-22
   PubMed Web of Science ®Google Scholar
• Weissman EM, Zhu CW, Schooler NR, et al. Lipid monitoring in patients with schizophrenia prescribed second-generation antipsychotics. J Clin Psychiatry 2006;67:1323-6
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Zhu B, Ernst FR, et al. The 3-year clinical and functional course of schizophrenia among individuals with and without diabetes at study entry. Prim Care Companion J Clin Psychiatry 2007;9:122-8
   PubMedGoogle Scholar
• Henderson K, Hudson T. Network-wide dissemination of antipsychotic monitoring protocol. MIRECC annual meeting. New Orleans, June 2005 [Abstract]
   Google Scholar
• Shi L, Ascher-Svanum H, Chiang YJ, et al. Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration. BMC Psychiatry 2009;9:80
   PubMed Web of Science ®Google Scholar
• Grundy SM, Brewer HB Jr, et al. National Heart, Lung, and Blood Institute: Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8
   Google Scholar
• Lean ME, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ 1995;311:158-61
   PubMed Web of Science ®Google Scholar
• Zhu S, Wang Z, Heshka S, et al. Waist circumference and obesity-associated risk factors among whites in the third National Health and Nutrition Examination Survey: clinical action thresholds. Am J Clin Nutr 2002;76:743-9
   PubMed Web of Science ®Google Scholar
• Calculate Your Body Mass Index. Available at: http://www.nhlbisupport.com/bmi [Last accessed 30 March 2008]
   Google Scholar
• Cramer J, Rosenheck R, Kirk G, et al., Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health 2003;6:566-73
   PubMed Web of Science ®Google Scholar
• Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997;50:105-16
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Zhu B, Faries D, et al. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry 2006;6:8
   PubMed Web of Science ®Google Scholar
• Haupt DW. Differential metabolic effects of antipsychotic treatments. Eur Neuropsychopharmacol 2006;16(Suppl. 3):S149-S155
   PubMed Web of Science ®Google Scholar
• Morrato EH, Cuffel B, Newcomer JW, et al. Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients. J Clin Psychopharmacol 2009;29:26-32
   PubMed Web of Science ®Google Scholar
• Morrato EH, Druss B, Hartung DM, et al. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch Gen Psychiatry 2010;67:17-24
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Faries DE, Zhu B, et al. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 2006;67:453-60
   PubMed Web of Science ®Google Scholar
• Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and healthcare costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004;161:692-9
   PubMed Web of Science ®Google Scholar